Chief Executive Officer
Revilico Inc
Christopher Korban is the Co-Founder and CEO of Revilico Inc., an AI-driven company developing an end-to-end AI + Physics based Operating System for small-molecule drug discovery. Revilico unifies quantum and generative chemistry, virtual cell biology, and robotic automation into one platform, empowering chemists and biologists to accelerate discovery from hypothesis to commercialization faster, cheaper, and with greater precision.
Christopher has pioneered computational strategies across ligand-protein binding chemistry, quantum chemistry (DFT), neural network potentials, and virtual cell modeling that link compound behavior to gene expression. His integration of robotic laboratory automation has enabled high-throughput screening of over 150,000 compounds, advancing predictive and generative drug-design models that redefine the frontiers of computational discovery.
Trained at UCLA, Christopher contributed to research at multiple labs. At the Molecular Screening Shared Resource (MSSR) under Dr. Robert Damoiseaux, he led high-throughput campaigns for rare, incurable genetic disease therapeutics. In the Di Carlo Lab, he developed point-of-care diagnostics; in I2BL, electrochemical biosensors for post-operative liver monitoring; and in the Wright Lab, polymer-protein bioconjugation for targeted cancer and diabetes therapies. His interdisciplinary foundation bridges AI, chemistry, and bioengineering to accelerate the next era of intelligent drug discovery.
Disclosure information not submitted.
Virtual Cells in Drug Discovery: A Physics-to-Intelligence Journey
Monday, November 10, 2025
3:00 PM - 3:15 PM CT